Objective To compare the efficacy of lisinopril and sacubitril-valsartan in patients with heart failure with preserved ejection fraction.Methods From January 2020 to February 2022,82 patients with heart failure with preserved e-jection fraction who were diagnosed and treated in our hospital were randomly divided into observation and control groups.There were 41 patients in both groups.The patients in the observation group were treated with sacubatrovalsartan,and the patients in the control group were treated with lisinopril.Through different drug treatments,the indexes of cardiac ultrasound before and after operation,clinical efficacy and adverse reactions after treatment were compared.Results After treatment,the indexes of cardiac function in both groups were improved,especially in the observation group(P＜0.05);The total clini-cal effective rate in the observation group was 90.24％higher than that in the control group(70.73％,P＜0.05);The total incidence of adverse reactions in the observation group was 7.32％lower than that in the control group(26.83％,P＜0.05).Conclusion In the treatment of heart failure patients with preserved ejection fraction,the effect of sacubatrovalsartan is better than that of lisinopril in terms of cardiac function,clinical efficacy and adverse reactions,and it is worth popularizing.
维普
万方数据